| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 109.1 | 109.2 | 97.6 |
| Other income | 3.8 | 2.8 | 1.7 |
| Total income | 112.9 | 112.0 | 99.3 |
| Profit before exceptional items & tax | 28.3 | 29.0 | 25.3 |
| Profit before tax | 28.3 | 29.0 | 25.3 |
| Net profit | 21.0 | 21.1 | 18.9 |
| Operating margin | 25.1% | 25.9% | 25.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +11.10% |
|---|---|
| Net profit, quarter on quarter | -0.50% |
| Revenue, year on year | +11.80% |
NSE results filing, NSE: VIMTALABS. Figures extracted from the filing.
Vimta Labs Ltd: key numbers
- Share price
- ₹570.05
- Market cap
- ₹2,548 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 32.0×Sector 53.1×
- Promoter holding
- 35.67%-0.18% QoQ
- FII holding
- 4.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Employee Stock Options
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.
Vimta Labs Credit Rating
CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.
Vimta Labs Price Movement Clarification
Vimta Labs clarified that recent increases in its share volume are due to market factors and not related to any undisclosed company information or developments.
Vimta Labs Adverse Business Impact
Vimta Labs reported a cyber security incident affecting its IT infrastructure. The company confirmed operations remain fully functional with no material impact identified thus far.
Vimta Labs Investor Presentation: Key Takeaways
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
- Call
- Guides 25% growth
Vimta Labs Other Announcement
Vimta Labs Ltd filed its quarterly shareholding pattern disclosure for the period ending June 30, 2026, pursuant to SEBI Regulation 31(1)(b).